Stay updated with breaking news from Text View. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.
/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today that based on the most recent...
It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat)
Investegate announcements from Ipsen Pharma, Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio